Oil Prices Jump as U.S.-Iran Conflict and Strait of Hormuz Tensions Shake Global Markets 
South Korea’s KOSPI Triggers Trading Curb as AI Chip Stock Selloff Deepens 
Gold Prices Fall as US-Iran Conflict, Rising Oil Prices Fuel Fed Rate Concerns 
Singapore GDP Grows 5.7% in Q2 2026 as AI-Driven Manufacturing Boosts Economy 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Asia Stocks Slip as Iran-Hormuz Tensions Lift Oil Prices, Dollar and Bond Yields 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Tabletop particle accelerator could transform medicine and materials science 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
US Stock Futures Slide as Iran Conflict Escalates Ahead of Key Q2 Earnings Week 
Asian Currencies Weaken as Stronger Dollar Weighs, Yen Supported by GPIF Repatriation Hopes 
Deutsche Bank Sees Global Capital Shifts Reshaping Long-Term U.S. Dollar Outlook 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
BOJ May Raise Japan Growth Forecast While Keeping Focus on Inflation Risks 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
China Trade Surplus Hits $125.6 Billion as June Exports, Imports Smash Forecasts 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
